Oncolytics Biotech opened higher at $0.41, compared with its previous close of $0.41. In the last trading session, the stock traded between $0.37 and $0.42. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Oncolytics Biotech is now worth
$ 34.26
Resulting in a loss of
$ 65.74 (65.74%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
$-0.04 (-10.11%)
Day High
$0.42
Day Low
$0.37
Day Open
$0.41
Prev Close
$0.41
Volume
7,94,623
1W Return
-13.35%
1M Return
-21.78%
3M Return
-54.66%
6M Return
-59.05%
1Y Return
-65.74%
Fundamentals
Market Cap ($ Mn)
47
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-1,678.03%
ROCE
-416.70%
EPS (TTM)
$-0.08
Investment Returns
1 Week
-13.35%
1 Month
-21.78%
3 Months
-54.66%
6 Months
-59.05%
9 Months
-56.65%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
Oncolytics signs supply deal with Coherus for anal cancer combo
Oncolytics Biotech signs clinical supply agreement with Coherus Oncology. Study evaluates pelareorep with LOQTORZI in squamous cell anal carcinoma. Trial expected to start Q1 2027 for patients progressing on first-line care. Builds on prior data showing doubled objective response rates in anal cancer. Targets $3 to $5 billion market across HPV-associated cancers.
Yesterday
20Oct
Oncolytics Biotech to present REO 033 trial data at ESMO 2026
Oncolytics Biotech presents REO 033 trial-in-progress data at ESMO 2026. Study evaluates pelareorep plus FOLFIRI/bevacizumab in second-line mCRC. Primary endpoint is objective response rate (ORR) in RAS-mutated MSS patients. Data builds on REO 022 results showing doubled efficacy metrics vs historical controls.
23 days ago
14Oct
Oncolytics sets Q4 2026 for anal cancer data; secures PanCAN grant
Final results for GOBLET Cohort 4 (anal carcinoma) expected in Q4 2026. Initial data for Cohort 5 (pancreatic cancer) anticipated in H1 2027. Median overall survival in Cohort 4 exceeds expectations per CMO. Enrollment complete for GOBLET study; infrastructure winding down.
